Biotest Stock

Biotest FCF Margin

Delisted

The Free Cash Flow Margin of Biotest (BIO.DE) as of Jul 31, 2026 is 4.43 %. In the previous year, Free Cash Flow Margin was -5.27 % — a change of -184.09% (higher).

FCF Margin

4.43 %

YoY

-184.09%

Last updated:

Free Cash Flow Margin of Biotest is 2026 4.43 % . Free Cash Flow Margin of Biotest was 2025 -5.27 % . It decreases by -184.09% higher compared to the previous year.
Access this data via the Eulerpool API

Biotest Stock analysis

What does Biotest do? Biotest AG is an innovative and successful company that operates in the fields of medicine, pharmacy, and biotechnology. It was founded in 1946 by Dr. Carl Adolf Vorherr in Dreieich near Frankfurt am Main. The company's original focus was on the development, production, and distribution of blood plasma products. In the 1950s, Biotest expanded into the field of transfusion medicine and began to clinically examine and process blood from donors. It became a leading manufacturer of concentrate preparations for the treatment of immune deficiencies and blood coagulation disorders in the 1960s. In the 1970s, the company became a leading manufacturer of monoclonal and polyclonal antibodies and an important research and development facility for biotechnological applications. Biotest today is divided into five research and business areas: Hematology & Immunology, Clinical Immunology, Biotherapeutics, Dermatology, and Research and Development. The company is globally present with locations in Europe, North America, Asia, and South America. It employs over 2,500 people and its products are available in more than 90 countries. It invests in research and development to stay at the forefront of technology and improve global health. Biotest is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biotest stock

Free Cash Flow Margin of Biotest is 4.43 % in 2026.

Access this data via the Eulerpool API

Margins — Biotest

All Key Metrics — Biotest